In patients with rapidly progressing SOD1 ALS, arimoclomol was found to be safe and well tolerated and provided therapeutic benefit across a range of efficacy outcome measures in a randomized, double-blind, placebo-controlled trial108. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.